Novel blindness gene therapy shows promise in first-in-human trial
The lowest dose of the gene therapy was shown to be safe and somewhat improved vision in the first three patients treated in the trial.
List view / Grid view
News
![A bottle of Advil over the counter pain medication [Credit: Rajarajan Kannanb/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Advil-bottle-300x278.jpg)
![A bottle of Advil over the counter pain medication [Credit: Rajarajan Kannanb/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Advil-bottle-e1618917106973.jpg)
Advil to reduce plastic waste through implementing new sustainable plastic technology
GSK Consumer Healthcare aims to reduce the plastic in all Advil bottles sold online and in store by 20 percent by 2022.
Enhertu® made available to breast cancer patients on UK’s Cancer Drugs Fund
Enhertu® (trastuzumab deruxtecan) has been made available to allow for more safety and efficacy data to be collected prior to the NICE’s decision about its routine use on the NHS.
FDA revokes bamlanivimab Emergency Use Authorization
The Emergency Use Authorization (EUA) was revoked after data suggested that, in the US, the prevalence of variants likely to be resistant to the monoclonal antibody bamlanivimab alone is increasing.
INO-4800 COVID-19 vaccine provides cross-reactive immune responses against variants
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
USP to release <922> Water Activity method for pharma
The new chapter, to be released in May, highlights the benefits of water activity measurement, as well as potential applications and best practices for use in pharmaceutical manufacturing.
Could precipitation reduce the cost of antibody production?
Using a new precipitation method eliminates the need for the costly chromatography process and could make antibody therapies more affordable to produce, according to Andrew Zydney.
Novel leishmaniasis vaccine safely induces immune responses in patients
The ChAd63-KH vaccine, used to treat leishmaniasis rather than prevent in this trial, significantly improved symptoms in patients with persistent post-kala-azar dermal leishmaniasis.
NT-300 tablets show promise in Phase III COVID-19 trial
Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
![Thermo Fisher Scientific company office with large company logo in Silicon Valley, US [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Thermo-Fisher-Scientific-300x278.jpg)
![Thermo Fisher Scientific company office with large company logo in Silicon Valley, US [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Thermo-Fisher-Scientific-e1618570463300.jpg)
Thermo Fisher to acquire PPD for over $17 billion
The acquisition, anticipated to complete in 2021, allows Thermo to expand its ‘one-stop-shop’ of services into running clinical trials.
Novavax’ COVID-19 vaccine to be included in UK’s mixed regimen study
Novavax has agreed to participate in the University of Oxford’s Com-COV2 study evaluating the safety and efficacy of regimens consisting of doses of COVID-19 vaccines from different manufacturers.
Rocket releases positive results from Leukocyte Adhesion Deficiency-I trial
Interim Phase I/II trial results show Rocket’s ex vivo lentiviral gene therapy candidate, RP-L201, is safe and of benefit to paediatric patients with severe Leukocyte Adhesion Deficiency-I.
Biologics CDMO market to double in value by 2026, suggests report
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
Novel natural killer cell engager therapy shows promise in Phase I trials
GTB-3550 TriKE™ monotherapy was found to restore natural killer cell function and immune surveillance in relapsed or refractory AML and MDS cancer patients.
Trial to assess anti-CD14 antibody as treatment for hospitalised COVID-19 patients
The trial will evaluate whether the novel IC14 anti-CD14 antibody can reduce recovery time and severity of COVID-19 symptoms in hospitalised patients.
